for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Clearside Biomedical Inc

CLSD.OQ

Latest Trade

0.73USD

Change

-0.00(-0.57%)

Volume

2,299

Today's Range

0.73

 - 

0.74

52 Week Range

0.56

 - 

6.41

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
0.73
Open
0.74
Volume
2,299
3M AVG Volume
19.90
Today's High
0.74
Today's Low
0.73
52 Week High
6.41
52 Week Low
0.56
Shares Out (MIL)
37.76
Market Cap (MIL)
27.72
Forward P/E
-0.81
Dividend (Yield %)
--

Latest Developments

More

Regenxbio Announces Exclusive Worldwide Option And License Agreement With Clearside Biomedical

Clearside Biomedical Provides New Drug Application Update For Xipere

Clearside Biomedical Q2 Loss Per Share $0.15

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Clearside Biomedical Inc

Clearside Biomedical, Inc. is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company's product candidates focus on diseases affecting three components of the eye: the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision; the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment, and the sclera, which is the outer protective layer of the eye. The Company’s lead product candidate, XIPERE, is a proprietary, preservative-free suspension of the corticosteroid triamcinolone acetonide formulated for administration via suprachoroidal injection.

Industry

Biotechnology & Drugs

Contact Info

900 N Point Pkwy Ste 200

+1.678.2703631

http://clearsidebio.com/

Executive Leadership

Christy L. Shaffer

Chairman of the Board

George Lasezkay

Interim Chief Executive Officer, Director

Charles A. Deignan

Chief Financial Officer

Leslie Zacks

Chief Compliance Officer, General Counsel

Thomas Crawford

Vice President - Supply Chain

Key Stats

2.29 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-1.970

2017

-2.330

2018

-2.690

2019(E)

-0.909
Price To Earnings (TTM)
--
Price To Sales (TTM)
231.03
Price To Book (MRQ)
2.15
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
78.28
LT Debt To Equity (MRQ)
61.06
Return on Investment (TTM)
-134.80
Return on Equity (TTM)
-113.09

Latest News

BRIEF-Clearside Biomedical Q1 Loss Per Share $0.62

* CLEARSIDE BIOMEDICAL ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Clearside Biomedical Reports Q4 Loss Per Share $0.65

* CLEARSIDE BIOMEDICAL ANNOUNCES FOURTH QUARTER 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Clearside Proposes Public Offering Of $75 Mln Of Shares

* CLEARSIDE ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Clearside Biomedical Provides Update On Two Phase 3 Clinical Trials Of CLS-TA In Retinal Vein Occlusion

* CLEARSIDE BIOMEDICAL PROVIDES UPDATE ON TWO PHASE 3 CLINICAL TRIALS OF CLS-TA IN RETINAL VEIN OCCLUSION

UPDATE 2-Clearside Biomedical's shares surge as eye drug succeeds in trial

* Shares surge 50 pct (Adds comments from analyst and conference call, background; updates share movement)

Clearside Biomedical's eye treatment succeeds late-stage study

Clearside Biomedical Inc said on Monday its treatment for fluid build-up in the eye had met the main goal of a late-stage study.

BRIEF-Clearside Biomedical Q3 loss per share $0.72

* Clearside Biomedical, Inc. Announces third quarter 2017 financial results and provides corporate update

BRIEF-Clearside Biomedical announces completion of patient enrollment in phase 2 clinical trial of CLS-TA

* Clearside Biomedical announces completion of patient enrollment in phase 2 clinical trial of CLS-TA used together with Eylea in patients with diabetic macular edema

BRIEF-Clearside Biomedical reports Q2 loss per share $0.54

* Announces second quarter 2017 financial results and provides corporate update

BRIEF-Clearside Biomedical completes patient enrollment in Phase 3 Peachtree Clinical Trial of CLS-TA

* Announces completion of patient enrollment in pivotal Phase 3 Peachtree Clinical Trial of CLS-TA for Suprachoroidal administration in patients with Macular Edema associated with non-infectious Uveitis

BRIEF-Clearside Biomedical announces first patient randomized in phase 2 clinical trial of CLS-TA

* Clearside Biomedical announces first patient randomized in phase 2 clinical trial of cls-ta used together with eylea in patients with diabetic macular edema

BRIEF-Clearside Biomedical files for mixed shelf offering of up to $250 mln - SEC Filing

* Clearside Biomedical Inc files for mixed shelf offering of up to $250 million - SEC Filing Source text: [http://bit.ly/2tDFDPJ] Further company coverage:

BRIEF-Clearside Biomedical ‍on June 30, entered into sales agreement with Cowen and Company, LLC - SEC Filing​

* Clearside Biomedical Inc - on June 30, 2017, Clearside Biomedical, Inc. entered into sales agreement with Cowen and Company, LLC - SEC Filing

BRIEF-Clearside Biomedical Q1 loss per share $0.41

* Clearside biomedical, inc. Announces first quarter 2017 financial results and provides corporate update

BRIEF-Clearside Biomedical provides update on diabetic macular edema trial

* Clearside biomedical, inc. Announces completion of patient enrollment in phase 1/2 open label clinical trial of cls-ta in diabetic macular edema

BRIEF-Clearside Biomedical enters into strategic collaboration with Eyekor

* Clearside Biomedical enters into strategic collaboration with Eyekor to support clinical development efforts Source text for Eikon: Further company coverage:

BRIEF-Clearside Biomedical reports Q4 loss per share $0.45

* Clearside Biomedical Inc announces fourth quarter and full year 2016 financial results

BRIEF-Clearside Biomedical says realignment for Axitinib for treatment of wet AMD towards DME program

* Initiated strategic realignment of research and development resources from pre-clinical Axitinib development program to DME clinical development program

BRIEF-Clearside Biomedical announces first patient enrolled in early-stage trial for treatment of Diabetic Macular Edema

* Clearside Biomedical, Inc. announces first patient enrolled in Phase 1/2 clinical trial of zuprata in Diabetic Macular Edema Source text for Eikon: Further company coverage:

BRIEF-Clearside Biomedical announces Q3 financial results

* Clearside Biomedical Inc -Phase 3 program of zuprata for macular edema associated with retinal vein occlusion to be initiated in first half of 2017

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up